Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 13 de 13
Filter
2.
Sci Rep ; 10(1): 348, 2020 01 15.
Article in English | MEDLINE | ID: mdl-31941926

ABSTRACT

Keap1 is a negative controller of the transcription factor Nrf2 for its activity. The Keap1/Nrf2 signaling pathway has been considered as a master regulator of cytoprotective genes, and exists in many cell types including osteoblasts and osteoclasts. Our previous study shows Nrf2 deletion decreases bone formation. Recent studies show hyperactivation of Nrf2 causes osteopenia in Keap1-/- mice, and Keap1-/- osteoblasts have significantly less proliferative potential than Keap1+/- osteoblasts. We aimed to examine if moderate Nrf2 activation by disruption of Keap1 impacts bone metabolism. We examined bone phenotype of Keap1 heterozygotic mice (Ht) in comparison with Keap1 wild type (WT) mice. Deletion or knockdown of Keap1 enhanced the gene expression of Nrf2, ALP and wnt5a in cultured primary osteoblasts compared to WT control. In male mice, compared with their age-matched littermate WT controls, Keap1 Ht mice showed significant increase in bone formation rate (+30.7%, P = 0.0029), but did not change the ultimate force (P < 0.01). The osteoclast cell numbers (-32.45%, P = 0.01) and surface (-32.58%, P = 0.03) were significantly reduced by Keap1 deficiency in male mice. Compared to male WT mice, serum bone resorption marker in male Keap1 Ht mice was significantly decreased. Our data suggest that moderate Nrf2 activation by disruption of Keap1 improved bone mass by regulating bone remodeling in male mice.


Subject(s)
Bone and Bones/metabolism , Kelch-Like ECH-Associated Protein 1/physiology , NF-E2-Related Factor 2/physiology , Osteogenesis/physiology , Animals , Bone Density/physiology , Bone Remodeling/genetics , Bone Remodeling/physiology , Cells, Cultured , Female , Gene Knockdown Techniques , Kelch-Like ECH-Associated Protein 1/genetics , Male , Mice , Mice, Inbred C57BL , Osteoblasts/physiology , Osteogenesis/genetics , Sex Characteristics
3.
Circ Res ; 122(12): 1703-1715, 2018 06 08.
Article in English | MEDLINE | ID: mdl-29703749

ABSTRACT

RATIONALE: Autologous bone marrow mesenchymal stem cells (MSCs) and c-kit+ cardiac progenitor cells (CPCs) are 2 promising cell types being evaluated for patients with heart failure (HF) secondary to ischemic cardiomyopathy. No information is available in humans about the relative efficacy of MSCs and CPCs and whether their combination is more efficacious than either cell type alone. OBJECTIVE: CONCERT-HF (Combination of Mesenchymal and c-kit+ Cardiac Stem Cells As Regenerative Therapy for Heart Failure) is a phase II trial aimed at elucidating these issues by assessing the feasibility, safety, and efficacy of transendocardial administration of autologous MSCs and CPCs, alone and in combination, in patients with HF caused by chronic ischemic cardiomyopathy (coronary artery disease and old myocardial infarction). METHODS AND RESULTS: Using a randomized, double-blinded, placebo-controlled, multicenter, multitreatment, and adaptive design, CONCERT-HF examines whether administration of MSCs alone, CPCs alone, or MSCs+CPCs in this population alleviates left ventricular remodeling and dysfunction, reduces scar size, improves quality of life, or augments functional capacity. The 4-arm design enables comparisons of MSCs alone with CPCs alone and with their combination. CONCERT-HF consists of 162 patients, 18 in a safety lead-in phase (stage 1) and 144 in the main trial (stage 2). Stage 1 is complete, and stage 2 is currently randomizing patients from 7 centers across the United States. CONCLUSIONS: CONCERT-HF will provide important insights into the potential therapeutic utility of MSCs and CPCs, given alone and in combination, for patients with HF secondary to ischemic cardiomyopathy. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT02501811.


Subject(s)
Heart Failure/therapy , Mesenchymal Stem Cell Transplantation/methods , Myocytes, Cardiac/cytology , Stem Cell Transplantation/methods , Combined Modality Therapy/methods , Double-Blind Method , Feasibility Studies , Heart Failure/etiology , Humans , Myocardial Ischemia/complications , Myocytes, Cardiac/chemistry , Proto-Oncogene Proteins c-kit , Research Design , Transplantation, Autologous , Treatment Outcome , Ventricular Dysfunction, Left/etiology , Ventricular Dysfunction, Left/therapy , Ventricular Remodeling
4.
Circulation ; 135(15): 1417-1428, 2017 Apr 11.
Article in English | MEDLINE | ID: mdl-28209728

ABSTRACT

BACKGROUND: Atherosclerotic peripheral artery disease affects 8% to 12% of Americans >65 years of age and is associated with a major decline in functional status, increased myocardial infarction and stroke rates, and increased risk of ischemic amputation. Current treatment strategies for claudication have limitations. PACE (Patients With Intermittent Claudication Injected With ALDH Bright Cells) is a National Heart, Lung, and Blood Institute-sponsored, randomized, double-blind, placebo-controlled, phase 2 exploratory clinical trial designed to assess the safety and efficacy of autologous bone marrow-derived aldehyde dehydrogenase bright (ALDHbr) cells in patients with peripheral artery disease and to explore associated claudication physiological mechanisms. METHODS: All participants, randomized 1:1 to receive ALDHbr cells or placebo, underwent bone marrow aspiration and isolation of ALDHbr cells, followed by 10 injections into the thigh and calf of the index leg. The coprimary end points were change from baseline to 6 months in peak walking time (PWT), collateral count, peak hyperemic popliteal flow, and capillary perfusion measured by magnetic resonance imaging, as well as safety. RESULTS: A total of 82 patients with claudication and infrainguinal peripheral artery disease were randomized at 9 sites, of whom 78 had analyzable data (57 male, 21 female patients; mean age, 66±9 years). The mean±SEM differences in the change over 6 months between study groups for PWT (0.9±0.8 minutes; 95% confidence interval [CI] -0.6 to 2.5; P=0.238), collateral count (0.9±0.6 arteries; 95% CI, -0.2 to 2.1; P=0.116), peak hyperemic popliteal flow (0.0±0.4 mL/s; 95% CI, -0.8 to 0.8; P=0.978), and capillary perfusion (-0.2±0.6%; 95% CI, -1.3 to 0.9; P=0.752) were not significant. In addition, there were no significant differences for the secondary end points, including quality-of-life measures. There were no adverse safety outcomes. Correlative relationships between magnetic resonance imaging measures and PWT were not significant. A post hoc exploratory analysis suggested that ALDHbr cell administration might be associated with an increase in the number of collateral arteries (1.5±0.7; 95% CI, 0.1-2.9; P=0.047) in participants with completely occluded femoral arteries. CONCLUSIONS: ALDHbr cell administration did not improve PWT or magnetic resonance outcomes, and the changes in PWT were not associated with the anatomic or physiological magnetic resonance imaging end points. Future peripheral artery disease cell therapy investigational trial design may be informed by new anatomic and perfusion insights. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT01774097.


Subject(s)
Cell- and Tissue-Based Therapy , Peripheral Arterial Disease/therapy , Aged , Aldehyde Dehydrogenase/metabolism , Bone Marrow Cells/metabolism , Bone Marrow Transplantation , Cell- and Tissue-Based Therapy/adverse effects , Cell- and Tissue-Based Therapy/methods , Comorbidity , Exercise , Extremities/blood supply , Female , Follow-Up Studies , Humans , Intermittent Claudication/therapy , Male , Middle Aged , Perfusion , Peripheral Arterial Disease/diagnosis , Peripheral Arterial Disease/metabolism , Quality of Life , Risk Factors , Treatment Outcome
5.
Circ Res ; 120(4): 692-700, 2017 Feb 17.
Article in English | MEDLINE | ID: mdl-28073804

ABSTRACT

RATIONALE: Acute kidney injury (AKI) is common during high-risk percutaneous coronary intervention (PCI), particularly in those with severely reduced left ventricular ejection fraction. The impact of partial hemodynamic support with a microaxial percutaneous left ventricular assist device (pLVAD) on renal function after high-risk PCI remains unknown. OBJECTIVE: We tested the hypothesis that partial hemodynamic support with the Impella 2.5 microaxial pLVAD during high-risk PCI protected against AKI. METHODS AND RESULTS: In this retrospective, single-center study, we analyzed data from 230 patients (115 consecutive pLVAD-supported and 115 unsupported matched-controls) undergoing high-risk PCI with ejection fraction ≤35%. The primary outcome was incidence of in-hospital AKI according to AKI network criteria. Logistic regression analysis determined the predictors of AKI. Overall, 5.2% (6) of pLVAD-supported patients versus 27.8% (32) of unsupported control patients developed AKI (P<0.001). Similarly, 0.9% (1) versus 6.1% (7) required postprocedural hemodialysis (P<0.05). Microaxial pLVAD support during high-risk PCI was independently associated with a significant reduction in AKI (adjusted odds ratio, 0.13; 95% confidence intervals, 0.09-0.31; P<0.001). Despite preexisting CKD or a lower ejection fraction, pLVAD support protection against AKI persisted (adjusted odds ratio, 0.63; 95% confidence intervals, 0.25-0.83; P=0.04 and adjusted odds ratio, 0.16; 95% confidence intervals, 0.12-0.28; P<0.001, respectively). CONCLUSIONS: Impella 2.5 (pLVAD) support protected against AKI during high-risk PCI. This renal protective effect persisted despite the presence of underlying CKD and decreasing ejection fraction.


Subject(s)
Acute Kidney Injury/prevention & control , Heart-Assist Devices/trends , Hemodynamics/physiology , Percutaneous Coronary Intervention/trends , Postoperative Complications/prevention & control , Acute Kidney Injury/etiology , Aged , Female , Heart-Assist Devices/adverse effects , Humans , Male , Middle Aged , Percutaneous Coronary Intervention/adverse effects , Postoperative Complications/etiology , Retrospective Studies , Risk Factors , Treatment Outcome
6.
J Intensive Care Med ; 32(2): 116-123, 2017 Feb.
Article in English | MEDLINE | ID: mdl-26768424

ABSTRACT

Prior to the advent of the coronary care unit (CCU), patients having an acute myocardial infarction (AMI) were managed on the general medicine wards with reported mortality rates of greater than 30%. The first CCUs are believed to be responsible for reducing mortality attributed to AMI by as much as 40%. This drastic improvement can be attributed to both advances in medical technology and in the process of health care delivery. Evolving considerably since the 1960s, the CCU is now more appropriately labeled as a cardiac intensive care unit (CICU) and represents a comprehensive system designed for the care of patients with an array of advanced cardiovascular disease, an entity that reaches far beyond its early association with AMI. Grouping of patients by diagnosis to a common physical space, dedicated teams of health care providers, as well as the development and implementation of evidence-based treatment algorithms have resulted in the delivery of safer, more efficient care, and most importantly better patient outcomes. The CICU serves as a platform for an integrated, team-based patient care delivery system that addresses a broad spectrum of patient needs. Lessons learned from this model can be broadly applied to address the urgent need to improve outcomes and efficiency in a variety of health care settings.


Subject(s)
Coronary Care Units/organization & administration , Delivery of Health Care, Integrated/organization & administration , Intensive Care Units , Myocardial Infarction/therapy , Resuscitation/methods , Thrombolytic Therapy/methods , Coronary Care Units/standards , Critical Care Nursing , Delivery of Health Care, Integrated/standards , Humans , Intensive Care Units/organization & administration , Intensive Care Units/trends , Myocardial Infarction/mortality , Telemetry
7.
Nat Rev Cardiol ; 10(9): 519-30, 2013 Sep.
Article in English | MEDLINE | ID: mdl-23856679

ABSTRACT

Heart failure is a devastating condition, the progression of which culminates in a mismatch of oxygen supply and demand, with limited options for treatment. Heart failure has several underlying causes including, but not limited to, ischaemic heart disease, valvular dysfunction, and hypertensive heart disease. Dysfunctional blood vessel formation is a major problem in advanced heart failure, regardless of the aetiology. Vascular endothelial growth factor (VEGF) is the cornerstone cytokine involved in the formation of new vessels. A multitude of investigations, at both the preclinical and clinical levels, have garnered valuable information on the potential utility of targeting VEGF as a treatment option for heart failure. However, clinical trials of VEGF gene therapy in patients with coronary artery disease or peripheral artery disease have not, to date, demonstrated clinical benefit. In this Review, we outline the biological characterization of VEGF, and examine the evidence for its potential therapeutic application, including the novel concept of VEGF as adjuvant therapy to stem cell transplantation, in patients with heart failure.


Subject(s)
Angiogenesis Inducing Agents/therapeutic use , Coronary Vessels/drug effects , Genetic Therapy , Heart Failure/therapy , Neovascularization, Physiologic/drug effects , Stem Cell Transplantation , Vascular Endothelial Growth Factor A/therapeutic use , Animals , Combined Modality Therapy , Coronary Vessels/metabolism , Coronary Vessels/physiopathology , Heart Failure/genetics , Heart Failure/metabolism , Heart Failure/physiopathology , Humans , Recombinant Proteins/therapeutic use , Treatment Outcome , Vascular Endothelial Growth Factor A/genetics , Vascular Endothelial Growth Factor A/metabolism
8.
Heart Surg Forum ; 16(2): E114-5, 2013 Apr.
Article in English | MEDLINE | ID: mdl-23625476

ABSTRACT

Left circumflex coronary artery anomalies are rare causes of cardiac symptoms, especially in the adult population. Herein we describe a case of a 40-year-old man presenting with stable angina who was found to have aneurysmal formation and fistulization of the left circumflex coronary artery to the coronary sinus. Contrast-enhanced multislice computed tomography was very useful in our case for the diagnosis of such anomalies.


Subject(s)
Angina Pectoris/diagnostic imaging , Angina Pectoris/etiology , Coronary Aneurysm/complications , Coronary Aneurysm/diagnostic imaging , Coronary Vessel Anomalies/complications , Coronary Vessel Anomalies/diagnostic imaging , Tomography, X-Ray Computed/methods , Adult , Contrast Media , Coronary Angiography/methods , Diagnosis, Differential , Humans , Male
9.
Curr Heart Fail Rep ; 10(1): 73-80, 2013 Mar.
Article in English | MEDLINE | ID: mdl-23354783

ABSTRACT

Cardiac repair through the use of regenerative medicine has been a considerable research focus over the last decade. Several stem cell types have been investigated over this timeframe as potential candidates to target post-infarction heart failure. The progression of investigation through the rigors of clinical trial design has provided some answers as to the potential clinical utility of this therapy; although there are many questions that remain. This review will concentrate on the clinical trial results of stem cell therapy for cardiac repair since the turn of the century and discuss some of the points that need clarification before this form of therapy can be considered for widespread applicability.


Subject(s)
Heart Failure/therapy , Stem Cell Transplantation/methods , Bone Marrow Transplantation/methods , Heart Failure/physiopathology , Humans , Mesenchymal Stem Cell Transplantation/methods , Muscle Development/physiology , Myoblasts, Skeletal/transplantation
10.
Circulation ; 126(11 Suppl 1): S54-64, 2012 Sep 11.
Article in English | MEDLINE | ID: mdl-22965994

ABSTRACT

BACKGROUND: SCIPIO is a first-in-human, phase 1, randomized, open-label trial of autologous c-kit(+) cardiac stem cells (CSCs) in patients with heart failure of ischemic etiology undergoing coronary artery bypass grafting (CABG). In the present study, we report the surgical aspects and interim cardiac magnetic resonance (CMR) results. METHODS AND RESULTS: A total of 33 patients (20 CSC-treated and 13 control subjects) met final eligibility criteria and were enrolled in SCIPIO. CSCs were isolated from the right atrial appendage harvested and processed during surgery. Harvesting did not affect cardiopulmonary bypass, cross-clamp, or surgical times. In CSC-treated patients, CMR showed a marked increase in both LVEF (from 27.5 ± 1.6% to 35.1 ± 2.4% [P=0.004, n=8] and 41.2 ± 4.5% [P=0.013, n=5] at 4 and 12 months after CSC infusion, respectively) and regional EF in the CSC-infused territory. Infarct size (late gadolinium enhancement) decreased after CSC infusion (by manual delineation: -6.9 ± 1.5 g [-22.7%] at 4 months [P=0.002, n=9] and -9.8 ± 3.5 g [-30.2%] at 12 months [P=0.039, n=6]). LV nonviable mass decreased even more (-11.9 ± 2.5 g [-49.7%] at 4 months [P=0.001] and -14.7 ± 3.9 g [-58.6%] at 12 months [P=0.013]), whereas LV viable mass increased (+11.6 ± 5.1 g at 4 months after CSC infusion [P=0.055] and +31.5 ± 11.0 g at 12 months [P=0.035]). CONCLUSIONS: Isolation of CSCs from cardiac tissue obtained in the operating room is feasible and does not alter practices during CABG surgery. CMR shows that CSC infusion produces a striking improvement in both global and regional LV function, a reduction in infarct size, and an increase in viable tissue that persist at least 1 year and are consistent with cardiac regeneration. CLINICAL TRIAL REGISTRATION: This study is registered with clinicaltrials.gov, trial number NCT00474461.


Subject(s)
Heart Failure/surgery , Myocardial Infarction/surgery , Stem Cell Transplantation , Atrial Appendage/cytology , Cell Survival , Combined Modality Therapy , Coronary Artery Bypass , Feasibility Studies , Heart/physiology , Heart Failure/etiology , Heart Ventricles/pathology , Humans , Magnetic Resonance Imaging , Myocardial Infarction/complications , Myocardial Infarction/pathology , Myocytes, Cardiac/pathology , Proto-Oncogene Proteins c-kit/analysis , Recovery of Function , Regeneration , Transplantation, Autologous , Ventricular Function, Left
11.
Curr Atheroscler Rep ; 14(5): 491-503, 2012 Oct.
Article in English | MEDLINE | ID: mdl-22847771

ABSTRACT

The increasing prevalence of heart failure, in the US and worldwide, poses a significant burden to patients, practitioners, and healthcare systems. Hence, there is a pressing need for alternative therapies to enhance the current treatment armamentarium. Accordingly, when considering heart failure of ischemic etiology, an intervention designed to regenerate the attending loss of myocardium could potentially result in improved cardiac function, functional status, and quality of life. Significant strides have been made by investigators in the study of stem cell therapy for cardiac repair; recently with cardiac-derived progenitor cells. These cells include cardiospheres, cardiosphere-derived cells, and c-kit positive cardiac stem cells. Herein, a review of both preclinical studies and phase I clinical trials of these cell types is presented. A detailed account of in vitro characterization, in vivo bioactivity, and safety and efficacy in humans is outlined. Thus far, encouraging results have been realized, although larger studies have yet to be undertaken.


Subject(s)
Cardiomyopathies/therapy , Myocardial Ischemia/therapy , Myocytes, Cardiac/cytology , Stem Cells/cytology , Animals , Cardiomyopathies/metabolism , Cell- and Tissue-Based Therapy , Humans , Myocardial Ischemia/metabolism , Myocytes, Cardiac/metabolism , Stem Cell Transplantation/methods , Stem Cells/metabolism
13.
Lancet ; 378(9806): 1847-57, 2011 11 26.
Article in English | MEDLINE | ID: mdl-22088800

ABSTRACT

BACKGROUND: c-kit-positive, lineage-negative cardiac stem cells (CSCs) improve post-infarction left ventricular (LV) dysfunction when administered to animals. We undertook a phase 1 trial (Stem Cell Infusion in Patients with Ischemic cardiOmyopathy [SCIPIO]) of autologous CSCs for the treatment of heart failure resulting from ischaemic heart disease. METHODS: In stage A of the SCIPIO trial, patients with post-infarction LV dysfunction (ejection fraction [EF] ≤40%) before coronary artery bypass grafting were consecutively enrolled in the treatment and control groups. In stage B, patients were randomly assigned to the treatment or control group in a 2:3 ratio by use of a computer-generated block randomisation scheme. 1 million autologous CSCs were administered by intracoronary infusion at a mean of 113 days (SE 4) after surgery; controls were not given any treatment. Although the study was open label, the echocardiographic analyses were masked to group assignment. The primary endpoint was short-term safety of CSCs and the secondary endpoint was efficacy. A per-protocol analysis was used. This study is registered with ClinicalTrials.gov, number NCT00474461. FINDINGS: This study is still in progress. 16 patients were assigned to the treatment group and seven to the control group; no CSC-related adverse effects were reported. In 14 CSC-treated patients who were analysed, LVEF increased from 30·3% (SE 1·9) before CSC infusion to 38·5% (2·8) at 4 months after infusion (p=0·001). By contrast, in seven control patients, during the corresponding time interval, LVEF did not change (30·1% [2·4] at 4 months after CABG vs 30·2% [2·5] at 8 months after CABG). Importantly, the salubrious effects of CSCs were even more pronounced at 1 year in eight patients (eg, LVEF increased by 12·3 ejection fraction units [2·1] vs baseline, p=0·0007). In the seven treated patients in whom cardiac MRI could be done, infarct size decreased from 32·6 g (6·3) by 7·8 g (1·7; 24%) at 4 months (p=0·004) and 9·8 g (3·5; 30%) at 1 year (p=0·04). INTERPRETATION: These initial results in patients are very encouraging. They suggest that intracoronary infusion of autologous CSCs is effective in improving LV systolic function and reducing infarct size in patients with heart failure after myocardial infarction, and warrant further, larger, phase 2 studies. FUNDING: University of Louisville Research Foundation and National Institutes of Health.


Subject(s)
Coronary Vessels , Myocardial Infarction/mortality , Myocardial Infarction/therapy , Stem Cell Transplantation/methods , Combined Modality Therapy , Coronary Artery Bypass/methods , Echocardiography, Doppler/methods , Female , Follow-Up Studies , Heart Failure/prevention & control , Heart Failure/therapy , Humans , Injections, Intra-Arterial , Magnetic Resonance Imaging/methods , Male , Middle Aged , Myocardial Infarction/diagnosis , Myocardial Ischemia/diagnosis , Myocardial Ischemia/mortality , Myocardial Ischemia/therapy , Myocytes, Cardiac/transplantation , Postoperative Care/methods , Prospective Studies , Reference Values , Risk Assessment , Survival Analysis , Time Factors , Tissue and Organ Harvesting , Transplantation, Autologous/methods , Treatment Outcome , Ventricular Remodeling/physiology
SELECTION OF CITATIONS
SEARCH DETAIL
...